Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events
21. Mai 2024 09:35 ET
|
Intrommune Therapeutics
Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events
Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya
12. März 2024 11:01 ET
|
Intrommune Therapeutics
Intrommune Therapeutics today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board.
Intrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy Treatment
22. Februar 2024 09:34 ET
|
Intrommune Therapeutics
OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects
AAFA Statement on Uber Eats Super Bowl Ad
08. Februar 2024 15:20 ET
|
Asthma and Allergy Foundation of America
Washington, DC, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) issued the following statement which may be attributed to Kenneth Mendez, president and CEO: ...
Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
06. Februar 2024 09:34 ET
|
Intrommune Therapeutics
New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy
Global Allergy Vaccine Market Report 2023: A $1.33 Billion Market in 2022 - Industry Size, Share, Trends, Opportunities, and Forecasts, 2018-2028F
24. Januar 2024 05:03 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Allergy Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ResearchAndMarkets.com's...
Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy
08. Januar 2024 09:05 ET
|
Intrommune Therapeutics
Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy
Global Peanut Allergy Treatment Market Report 2024: Analysis by Drug Class, Antihistamines, Epinephrine - Forecasts to 2030
05. Januar 2024 09:03 ET
|
Research and Markets
Dublin, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The "Global Peanut Allergy Treatment Market Size, Share & Trends Analysis Report by Drug Class (Antihistamines, Epinephrine), Route Of Administration,...
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy
09. November 2023 11:01 ET
|
Intrommune Therapeutics
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy
Peanut Allergy Market to Accelerate Substantially by 2032, Examines DelveInsight | Leading Companies - Vedanta, Allergy, COUR Pharmaceutical, DBV, Aimmune, Novartis, NIAID, Alladapt Immunotherapeutics
12. September 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Peanut Allergy Market to Accelerate Substantially by 2032, Examines DelveInsight | Leading Companies - Vedanta, Allergy, COUR Pharmaceutical, DBV,...